Dolutegravir Use at Conception - Additional Surveillance Data from Botswana

N Engl J Med. 2019 Aug 29;381(9):885-887. doi: 10.1056/NEJMc1908155. Epub 2019 Jul 22.

Authors

Mmakgomo M Raesima¹, Chibuike M Ogbuabo², Vasavi Thomas³, Sara E Forhan⁴, Gadzikanani Gokatweng², Eldah Dintwa¹, Chipo Petlo¹, Catherine Motswere-Chirwa⁵, Elizabeth M Rabold⁴, Sarah C Tinker⁴, Shifawu Odunsi⁶, Sifelani Malima¹, Omphemetse Mmunyane¹, Thusoetsile Modise¹, Kelame Kefitlhile¹, Kunle Dare⁵, Mpho Letebele⁵, Michelle E Roland⁵, Cynthia A Moore⁴, Surbhi Modi⁴, Dhelia M Williamson⁴

Affiliations

¹ Botswana Ministry of Health and Wellness, Gaborone, Botswana.
² Botswana-University of Maryland School of Medicine Health Initiative, Gaborone, Botswana.
³ Centers for Disease Control and Prevention, Gaborone, Botswana [email protected].
⁴ Centers for Disease Control and Prevention, Atlanta, GA.
⁵ Centers for Disease Control and Prevention, Gaborone, Botswana.
⁶ Peace Corps, Gaborone, Botswana.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Botswana / epidemiology
Female
Fetus / drug effects
HIV Infections / drug therapy*
HIV Integrase Inhibitors / adverse effects*
HIV Integrase Inhibitors / therapeutic use
Heterocyclic Compounds, 3-Ring / adverse effects*
Heterocyclic Compounds, 3-Ring / therapeutic use
Humans
Infant, Newborn
Neural Tube Defects / chemically induced*
Neural Tube Defects / epidemiology
Oxazines
Piperazines
Population Surveillance
Pregnancy
Pregnancy Complications, Infectious / drug therapy*
Prevalence
Pyridones

Substances

HIV Integrase Inhibitors
Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
dolutegravir

Grants and funding